DiLun Biotechnology pushes automated peptide synthesis systems

By AI, Created 11:16 AM UTC, May 20, 2026, /AGP/ – Beijing DiLun Biotechnology is highlighting its PepAxis peptide synthesizer line as demand rises for faster, more precise peptide drug development. The company is pitching R&D, pilot and industrial systems that it says support higher throughput, cleaner operations and tighter regulatory tracking.

Why it matters: - Peptide therapeutics are expanding as drug makers pursue treatments for metabolic disease, oncology and antimicrobial use cases. - The shift toward automated synthesis is raising demand for systems that improve reproducibility, cut human error and support regulatory compliance. - DiLun Biotechnology is positioning its PepAxis™ platform as infrastructure for both discovery work and commercial-scale peptide manufacturing.

What happened: - Beijing DiLun Biotechnology Co., Ltd. said it continues to expand its global profile as a manufacturer of peptide synthesizers through its PepAxis™ technology brand. - The company’s PepAxis™ product line covers solid-phase peptide synthesis equipment for pharmaceutical and research users. - DiLun highlighted R&D, pilot and industrial systems in the PepAxis family, along with automated cleavage and precipitation equipment. - The company directed readers to more information and technical specifications.

The details: - PepAxis™ systems use 180° up-down mixing technology with zero dead angles and microwave-assisted capabilities. - DiLun says the design aims to improve purity and efficiency in molecular construction. - The R&D Scale line includes the Nova1 and Nova5 Microwave systems. - The Nova5 system uses microwave-assisted solid-phase synthesis to speed reaction steps. - The Atlas Pilot Scale and Sirius Industrial Grade systems include large-volume dual-jacket temperature-controlled reactors. - Those systems provide real-time monitoring of pressure, temperature and stirring speed. - DiLun says the industrial systems can reduce cleaning solvent usage by up to 40%. - The Sirius model uses metering pumps for quantitative solvent transfer. - The Tetras system can manage up to 106 independent reactors for high-throughput asynchronous synthesis. - The Aquila series supports automated cleavage and precipitation through a modular three-vessel workflow covering cleavage, concentration and precipitation. - The company says its equipment is used in academic and corporate R&D labs, clinical API manufacturing and large-scale pharmaceutical production. - DiLun says its client base includes research universities, global contract research organizations and pharmaceutical manufacturers. - Customized industrial-grade cleavage systems can be integrated into a client’s existing workflow.

Between the lines: - The release frames peptide synthesis hardware as a strategic layer in biotech, not just a lab instrument category. - The emphasis on automation, monitoring and solvent reduction suggests a sales pitch aimed at both regulatory pressure and sustainability goals. - The broad product range signals an effort to serve customers from early discovery through production, which can deepen relationships across the drug-development pipeline.

What’s next: - DiLun is likely to keep pushing its PepAxis platform as peptide drug pipelines grow more complex. - The company is betting that demand will continue to favor systems that combine throughput, precision, data logging and lower resource use. - The official website remains the company’s main channel for product details and specifications.